Asahi Kasei consolidates global pharma units under Asahi Kasei Therapeutics brand
Bitget2026/09/29 12:31- Asahi Kasei will consolidate its global pharma operations under the Asahi Kasei Therapeutics brand, creating a unified management structure.
- The reorganization folds Japan-based Asahi Kasei Therapeutics, US-based Veloxis, Sweden’s Calliditas, and Germany’s newly acquired AiCuris into one platform.
- Move supports a target of JPY 300 billion in pharmaceutical net sales by FY2030, with capital allocation set at a global level.
- Plan includes about JPY 40 billion for in-licensing over three years, alongside continued investment in existing products and pipeline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Amid opposition to data centers, Musk doubles down: SpaceX (SPCX.US) plans to build a $24 billion computing center and gas power plant in Texas.
According to a public hearing notice published on the Starbase website, SpaceX plans to build, own, and operate a gas-fired power plant and a supercomputing facility at its company town in Starbase, Texas.
Crypto prices
More
